Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy.

Published

Journal Article

BACKGROUND: The purpose of this analysis was to assess rates of symptomatic remission in patients with bipolar mania receiving risperidone in a double-blind, parallel-group, multicenter, placebo-controlled trial conducted in India. METHOD: Two hundred ninety-one adult patients who met DSM-IV criteria for bipolar I disorder manic or mixed episode were randomly assigned to flexible doses of risperidone (1-6 mg/day, N = 146) or placebo (N = 145) for up to 3 weeks. An entry Young Mania Rating Scale (YMRS) score of >or= 20 was required at trial screening and baseline. Remission was defined as achieving and maintaining a YMRS score

Full Text

Duke Authors

Cited Authors

  • Gopal, S; Steffens, DC; Kramer, ML; Olsen, MK

Published Date

  • August 2005

Published In

Volume / Issue

  • 66 / 8

Start / End Page

  • 1016 - 1020

PubMed ID

  • 16086617

Pubmed Central ID

  • 16086617

International Standard Serial Number (ISSN)

  • 0160-6689

Digital Object Identifier (DOI)

  • 10.4088/jcp.v66n0809

Language

  • eng

Conference Location

  • United States